Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report
Calliditas Therapeutics will release its Q3 2020 business update on November 12, 2020, at 07:00 am CET. A telephone conference with a presentation of the results will be held at 2:30 pm CET, hosted by CEO Renée Aguiar-Lucander and CFO Fredrik Johansson. The presentation will be accessible on the company's website and via audio cast. Dial-in numbers are provided for participation. Calliditas, focused on orphan indications, is advancing its lead product Nefecon for IgA nephropathy and is listed under ticker CALT.
- None.
- None.
STOCKHOLM, Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas will also host a telephone conference, which will include a presentation of the results, on the same day at 2:30 pm CET. The event will be hosted by the company's CEO, Renée Aguiar-Lucander, and CFO Fredrik Johansson. The presentation will be held in English.
The presentation will be live on the company's website during the call under Financial Reports and Presentations and will also be made available online after the call. To participate in the telephone conference, please use the dial-in details shown below:
Dial-in numbers, SE: +46856642707 UK: +443333009034 US: +18332498405
A link to audio cast can be found on the Calliditas website under Financial Reports and Presentations or here:
https://financialhearings.com/event/12809
The information was released for public disclosure on November 11, 2020 at 11:00 a.m CET.
For further information, please contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 7955129845, email: marie.galay@calliditas.com
About Calliditas
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-to-host-conference-call-to-provide-business-update-and-2020-q3-report-301170783.html
SOURCE Calliditas Therapeutics
FAQ
When will Calliditas Therapeutics release its Q3 2020 report?
What time is the Calliditas conference call for Q3 2020 results?
Who will host the Calliditas Q3 2020 conference call?
How can I participate in the Calliditas Q3 2020 conference call?
What is the focus of Calliditas Therapeutics?
What is Calliditas' lead product candidate?
Under which ticker is Calliditas listed?
